10-Q/A: Bio Essence Corp. Files Amended 10-Q Report Following Internal Control Review

Bio Essence Corp. has filed an amendment to its Form 10-Q for the quarter ended June 30, 2024, to update disclosures regarding internal controls, while the rest of the report remains unchanged.

Summary

• Bio Essence Corp. has filed an amendment to its quarterly report on Form 10-Q for the period ended June 30, 2024, primarily to update disclosures regarding the company's internal controls.
• The company's financial statements for the quarter ending March 31, 2024, were restated due to errors in accounting for certain historical transactions under US GAAP.
• The company reported a net loss of $81,740 for the six months ended June 30, 2024, compared to a net loss of $463,351 for the same period in 2023.
• Revenues from continuing operations were $41,695 for the six months ended June 30, 2024, compared to $0 for the same period in 2023.
• The company sold its subsidiaries, Bio Essence Pharmaceutical Inc. (BEP) and Bio Essence Herbal Essentials, Inc. (BEH), for $300,000 and $400,000 respectively, resulting in a gain on disposal of $67,451 and $377,752.
• The company's accumulated deficit from continuing operations was $9,222,214 as of June 30, 2024, raising concerns about its ability to continue as a going concern.
• The company is exploring options to raise additional funds through private or public offerings, or by obtaining loans.
• The company had a working capital deficit of $2,192,611 and a current ratio of 0.29:1 as of June 30, 2024.
• The company's management has identified deficiencies in its internal controls over financial reporting.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including a large accumulated deficit, working capital deficit, and going concern issues. While there are some positive developments like increased revenue and reduced losses, the overall sentiment is negative due to the company's precarious financial position and internal control weaknesses.

Positives

• The company's net loss decreased significantly to $81,740 for the six months ended June 30, 2024, compared to $463,351 for the same period in 2023.
• The company generated $41,695 in revenue from continuing operations for the six months ended June 30, 2024, compared to no revenue in the same period of 2023.
• The sale of BEP and BEH generated a total gain of $445,203.
• The company is actively seeking new business opportunities and exploring potential acquisitions.

Negatives

• The company has a substantial accumulated deficit of $9,222,214 as of June 30, 2024.
• The company's current liabilities significantly exceed its current assets, resulting in a working capital deficit of $2,192,611.
• The company's management has identified deficiencies in its internal controls over financial reporting.
• The company's ability to continue as a going concern is dependent on its ability to generate sufficient revenue and raise additional funds.

Risks

• The company's substantial accumulated deficit and working capital deficit raise concerns about its financial stability.
• The company's ability to continue as a going concern is dependent on its ability to generate sufficient revenue and raise additional funds, which is not guaranteed.
• The identified deficiencies in internal controls over financial reporting could lead to further financial misstatements.
• The company's reliance on loans from a major shareholder poses a risk if those funds become unavailable.

Future Outlook

The company intends to raise additional funds through private or public offerings, or by obtaining loans, and is actively seeking other business opportunities including expanding OEM business and looking for potential acquisition targets.

Management Comments

• Management intends to raise funds by way of a private or public offering, or by obtaining loans from banks or others.
• Management believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds on reasonable terms and conditions.
• Management is working to develop and implement controls and procedures.

Industry Context

The health supplement industry is competitive, and Bio Essence Corp. is facing challenges in generating revenue and maintaining financial stability. The company's strategic shift to focus on OEM services and potential acquisitions reflects a broader trend in the industry to diversify and consolidate.

Comparison to Industry Standards

• The company's current ratio of 0.29:1 is significantly below the industry average, indicating a high level of short-term financial risk.
• Many companies in the health supplement industry have a current ratio of 1:1 or higher.
• The company's accumulated deficit of $9,222,214 is also a significant concern compared to industry peers.
• The company's reliance on loans from a major shareholder is not a typical practice in the industry and indicates a lack of access to traditional financing.

Related Party Transactions

• The company has loans from a major shareholder (also a senior officer) totaling $1,365,246 as of June 30, 2024.
• The company has a loan from another major shareholder for $608,631 for settling litigation.
• On May 31, 2023, the Board of Directors approved a debt-to-equity conversion with Ms. Yan, the CEO and major shareholder, for 5,000,000 shares in exchange for $2,500,000 debt.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential dilution from future capital raises.
• Employees may be concerned about job security due to the company's going concern issues.
• Customers may be impacted by potential disruptions in the company's operations.
• Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will continue to seek additional funding through private or public offerings, or by obtaining loans.
• The company will continue to explore other business opportunities including expanding OEM business and looking for potential acquisition targets.
• Management will continue to work to develop ICFR and controls over reporting procedures.

Key Dates

Keywords

internal controls, financial statements, going concern, net loss, revenue, discontinued operations, working capital, debt, equity, restatement